320 related articles for article (PubMed ID: 17266632)
1. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
Chaput JP; St-Pierre S; Tremblay A
Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
[TBL] [Abstract][Full Text] [Related]
2. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
5. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Leung WY; Thomas GN; Chan JC; Tomlinson B
Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
[TBL] [Abstract][Full Text] [Related]
6. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
Richter WO
MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz E; Martín Folgueras T
Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
9. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
11. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio MJ; Wilton LV; Shakir SA
Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
[TBL] [Abstract][Full Text] [Related]
12. Long-term pharmacotherapy for obesity.
Klein S
Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
[TBL] [Abstract][Full Text] [Related]
13. What are the risks and the benefits of current and emerging weight-loss medications?
Robinson JR; Niswender KD
Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
[TBL] [Abstract][Full Text] [Related]
14. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment of obesity].
Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
17. [Anti-obesity drugs: sibutramine and orlistat].
Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
[No Abstract] [Full Text] [Related]
18. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
[TBL] [Abstract][Full Text] [Related]
19. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
